Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 6/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7495766 | 1.00 | CA2 (0.58) | CA2CASP1PPARAPPARGMMP13 | |
| SCHEMBL7495758 | 1.00 | CA2 (0.58) | CA2CASP1PPARAPPARGMMP13 | |
| SCHEMBL5228626 | 0.98 | CA2 (0.56) | CA2CASP1PPARAPPARGMMP13 | |
| SCHEMBL5230909 | 0.89 | CASP1 (0.52) | CA2CASP1PPARAPPARGMMP13 | |
| SCHEMBL6487973 | 0.87 | CASP1 (0.62) | CA2CASP1PPARAPPARGMMP13 | |
| SCHEMBL1541597 | 0.87 | CASP1 (0.62) | CA2CASP1PPARAPPARGMMP13 | |
| SCHEMBL4973400 | 0.87 | CASP1 (0.62) | CA2CASP1PPARAPPARGMMP13 | |
| SCHEMBL7492863 | 0.86 | MTNR1A (0.45) | CA2CASP1 | |
| SCHEMBL7493194 | 0.86 | MTNR1A (0.45) | CA2CASP1 | |
| SCHEMBL7492869 | 0.86 | MTNR1A (0.45) | CA2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0969000-B1 | Process for reducing alpha-amino ketones | KANEKA CORP (JP) | 2002-12-04 | — | — | EP | claimed |
| US-6255522-B1 | USING AS REDUCING AGENT A REACTION PRODUCT OF ORGANOALUMINUM COMPOUND, SULFONATE AND ALCOHOL | KANEKA CORPORATION (JP) | 2001-07-03 | — | — | US | claimed |
| EP-0969000-A1 | PROCESS FOR REDUCING $G(a)-AMINO KETONES | KANEKA CORPORATION (JP) | 2000-01-05 | — | — | EP | claimed |
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| US-RE38796-E1 | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | AJINOMOTO CO.,INC. (JP) | 2005-09-13 | — | — | US | disclosed |
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-0972760-B1 | PROCESS FOR THE PURIFICATION OR ISOLATION OF (2S, 3R)-1-HALO-2-HYDROXY-3-(PROTECTED AMINO)-4-PHENYLTHIOBUTANES OR OPTICAL ANTIPODES THEREOF | KANEKA CORP (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6693199-B2 | DEPROTECTING CARBAMATE GROUP AND AMIDATING IN PRESENCE OF SUCH AS HYDROXYBENZOTRIAZOLE HYDRATE PROMOTER | AGOURON PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030216569-A1 | Method of making HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2003-11-20 | — | — | US | disclosed |
| US-6525215-B2 | As antiviral agents suitable for therapy of patients or hosts infected with the HIV virus, which is known to cause AIDS | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-0969000-B1 | Process for reducing alpha-amino ketones | KANEKA CORP (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-0763017-A1 | N-(3-AMINO-2-HYDROXYBUTYL)SULPHONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0741719-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5527829-A | VIRICIDES; TREATING AIDS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-06-18 | — | — | US | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995032185-A1 | N-(3-AMINO-2-HYDROXYBUTYL)SULPHONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995021164-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216569-A1 | Method of making HIV protease inhibitors | SERPINB1, PRSS1, PREP | CA2 3472/4885CASP1 80/4885PPARA 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.